In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schwarz Shops Fesoterodine to Pfizer

Executive Summary

Pfizer Inc.'s acquisition of worldwide rights to Schwarz's registration-stage incontinence product fesoterodine for $210 million plus royalties is the most recent milestone in the German company's successful integration of drug development to its legacy marketing organization-and one that nearly guarantees it a substantial revenue stream regardless of how fesoterodine fares in the marketplace.
Advertisement

Related Content

Pfizer Toviaz Clears FDA For OAB: Three-Year Window To Establish Detrol Successor
European Consolidation: Serious Competition for Big Pharma?
European Consolidation: Serious Competition for Big Pharma?
Pliva: Two Steps Forward, One Step Back?
Pliva: Two Steps Forward, One Step Back?
Can Political M&A Make Commercial Sense?
Schwarz: The Omeprazole Opportunity

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel